Efficacy of gosogliptin in the treatment of type 2 diabetes mellitus: a clinical case

Background. At the start of therapy for carbohydrate metabolism disorders with the prescription of one or two oral antihyperglycemic agents (OADs), the probability of persistent and long-term compensation is very high. With timely diagnosis of carbohydrate metabolism disorders, the measures taken can significantly delay progression to the DM2 diagnosis.

Description of the clinical case. This article presents a detailed clinical case of a patient with type 2 diabetes mellitus, which developed from prediabetes due to the patient’s long-term ignorance of his condition. With insufficient patient awareness and a negligent attitude towards his health, taking into account the presence of risk factors, the progression of carbohydrate metabolism disorders was a matter of time. Thus, the treatment prescribed to the patient with prediabetes did not lead to the desired results. After diagnosis of DM2 and prescription of OADs, stable normalization of glycemic levels was achieved. Subsequently, sulfonylureas were replaced with a combination of gosogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin, which proved effective for a year.

Conclusion. This case demonstrates how the lack of timely medical intervention and poor adherence to therapy led to worsening metabolic disorders, which required a more aggressive approach to treatment.

First-line drugs, such as metformin and DPP-4 inhibitors, help normalize glucose levels and restore metabolic homeostasis. This reduces the risk of DM2-associated complications.

Early diagnosis and therapy stabilize the patient’s condition, delaying the need for aggressive treatment methods. They also improve quality of life and reduce the risk of cardiovascular complications. Continuous monitoring and adaptation of therapy are key elements of successful management of prediabetes and early DM2 stages. Thus, early detection and intervention in carbohydrate metabolism disorders prevent progression to DM2, improving the prognosis for patients.